12,000 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Generate Investment Management Ltd

Generate Investment Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 12,000 shares of the biopharmaceutical company’s stock, valued at approximately $6,300,000.

Other large investors also recently bought and sold shares of the company. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock valued at $6,836,000 after purchasing an additional 2,501 shares during the period. Sepio Capital LP increased its holdings in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 842 shares in the last quarter. Founders Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Regeneron Pharmaceuticals by 9.4% during the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock valued at $94,779,000 after acquiring an additional 12,793 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.5%

NASDAQ REGN opened at $563.90 on Monday. The business has a fifty day moving average price of $569.79 and a 200 day moving average price of $569.50. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,070.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market cap of $59.77 billion, a P/E ratio of 14.21, a P/E/G ratio of 1.80 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on REGN shares. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research report on Monday, August 4th. Citigroup reiterated a “buy” rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Canaccord Genuity Group restated a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.